Generalized Myasthenia Gravis (gMG) - Epidemiology Forecast - 2032

This ‘Generalized Myasthenia Gravis (gMG)- Epidemiology Forecast - 2032' report delivers an in-depth understanding of Generalized Myasthenia Gravis (gMG) historical and forecasted epidemiology in the United States, EU-5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Generalized Myasthenia Gravis (gMG) Disease Understanding

Myasthenia gravis (MG) is an autoimmune disease that occurs when the immune system attacks the body's own tissues. In MG, that attack interrupts the connection between nerve and muscle - the neuromuscular junction. MG is characterized mostly by autoantibodies against the acetylcholine receptor (AChR-Ab) or against a receptor-associated protein called muscle-specific tyrosine kinase (MuSK-Ab).

Generalized Myasthenia Gravis (gMG) Epidemiology

The Generalized Myasthenia Gravis (gMG) epidemiology division provides insights about the historical and prevalent patient pool, along with the forecasted trend for all the seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The report also provides the diagnosed patient pool, trends, and assumptions.

Key Findings

The total diagnosed prevalent cases of Generalized Myasthenia Gravis (gMG) patients in the 7MM are increasing during the study period, i.e., 2019-2032.

The disease epidemiology covered in the report provides historical as well as forecasted Generalized Myasthenia Gravis (gMG) epidemiology segmented as the total diagnosed prevalent cases of Generalized Myasthenia Gravis (gMG), gender-specific cases of Generalized Myasthenia Gravis (gMG), and antibodies-specific cases of Generalized Myasthenia Gravis (gMG). The report includes the diagnosed prevalent cases scenario of Generalized Myasthenia Gravis (gMG) in the 7MM covering the United States, the EU-5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.

Country-wise Generalized Myasthenia Gravis (gMG) Epidemiology

The epidemiology segment also provides the Generalized Myasthenia Gravis (gMG) epidemiology data and findings across the United States, the EU-5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The diagnosed prevalent cases of Generalized Myasthenia Gravis (gMG) associated in the 7MM countries were approximately 116,100 in 2021.

• As per the estimates, the United States has the largest diagnosed prevalent population of Generalized Myasthenia Gravis (gMG)
• Among the EU5 countries, Germany had the highest diagnosed prevalent cases of Generalized Myasthenia Gravis (gMG), followed by the United Kingdom. On the other hand, Italy had the lowest diagnosed prevalent cases with around 8,800 cases in 2021.

Scope of the Report

• The Generalized Myasthenia Gravis (gMG) report covers a detailed overview explaining its causes, symptoms, and classification, pathophysiology, diagnosis, and treatment patterns.
• The Generalized Myasthenia Gravis (gMG) Epidemiology Report and Model provide an overview of Generalized Myasthenia Gravis (gMG)' risk factors and global trends in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
• The report provides insight into Generalized Myasthenia Gravis (gMG)' historical and forecasted patient pool in the seven major markets covering the United States, the EU-5 (Germany, Spain, France, Italy, UK), and Japan.
• The report helps to recognize the growth opportunities in the 7MM concerning the patient population.
• The report assesses the disease risk and burden and highlights the unmet needs of Generalized Myasthenia Gravis (gMG).
• The report provides the segmentation of the Generalized Myasthenia Gravis (gMG) epidemiology by the Diagnosed Prevalent Cases of Generalized Myasthenia Gravis (gMG) in the 7MM.
• The report provides the Generalized Myasthenia Gravis (gMG) epidemiology segmentation by gender-specific cases of Generalized Myasthenia Gravis (gMG) in the 7MM.
• The report provides the Generalized Myasthenia Gravis (gMG) epidemiology segmentation by antibodies-specific cases of Generalized Myasthenia Gravis (gMG) in the 7MM.

Report Highlights

• 11-year Forecast of Generalized Myasthenia Gravis (gMG) epidemiology
• 7MM Coverage
• Diagnosed Prevalent Cases of Generalized Myasthenia Gravis (gMG)
• Gender-specific cases of Generalized Myasthenia Gravis (gMG)
• Antibodies-specific Cases of Generalized Myasthenia Gravis (gMG)

KOL Views

The publisher interviews KOLs, and SMEs' opinions through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

• What are the major factors that will drive the change in the patient population in Generalized Myasthenia Gravis (gMG) during the forecast period (2019-2032)?
• What are the key findings of the Generalized Myasthenia Gravis (gMG) epidemiology across the 7MM, and which country will have the highest number of patients during the forecast period (2019-2032)?
• What would be the total number of Generalized Myasthenia Gravis (gMG) patients across the 7MM during the forecast period (2019-2032)?
• Among the EU-5 countries, which country will have the highest number of patients during the forecast period (2019-2032)?
• At what CAGR the patient population is expected to grow in the 7MM during the forecast period (2019-2032)?
• What are the disease risks, burden, and unmet needs of Generalized Myasthenia Gravis (gMG) market?
• What are the current treatment patterns for Generalized Myasthenia Gravis (gMG)?

Reasons to Buy

The Generalized Myasthenia Gravis (gMG) epidemiology report will allow the user to -

• Develop business strategies by understanding the trends shaping and driving the global Generalized Myasthenia Gravis (gMG) market.
• Quantify patient populations in the global Generalized Myasthenia Gravis (gMG) market to improve product design, pricing, and launch plans.
• Organize sales and marketing efforts by identifying the gender that present the best opportunities for Generalized Myasthenia Gravis (gMG) therapeutics in each market covered.
• Understand the magnitude of the Generalized Myasthenia Gravis (gMG) population by its diagnosed prevalence.
• Understand the magnitude of the Generalized Myasthenia Gravis (gMG) population by its Gender-specific cases.
• Understand the magnitude of the Generalized Myasthenia Gravis (gMG) population by its Antibodies-specific cases.
• The Generalized Myasthenia Gravis (gMG) epidemiology report and model were written and developed by Masters and PhD level epidemiologists.
• The Generalized Myasthenia Gravis (gMG) Epidemiology Model developed by the publisher is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 11-year forecast period using reputable sources.

Key Assessments

• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Geographies Covered

• The United States
• EU-5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2019-2032